The singer of the iconic punk group The New York Dolls has been secretly battling stage 4 cancer for the last several years.

David Johansen's wife of over a decade, Mara Hennessey, told Fox News Digital about his diagnosis.

"David has been living with stage 4 cancer for several years. He’s undergone chemo, radiation, immunotherapy and surgery, and weathered all the side effects and consequences of the various treatments, all with his indomitable spirit and incomparable sense of humor.

"He’s been nurtured by the love of his wife and daughter, while trying to spare his friends, colleagues, and fans and keep his troubles private. He’s always been like this," Hennessey said.

DAVE COULIER'S CANCER BATTLE IS GETTING ‘MORE DIFFICULT,’ BUT THIS MORNING RITUAL HELPS HIM PULL THROUGH

"He claims it’s because he’s half Norwegian," she continued.

Hennessey explained that the financial burden has taken a toll on their family.

"Our family have reached the point where we need more support. We’ve run up some serious debt caring for our beloved David, and are facing still more unmanageable expenses. This trying to be low-key is not sustainable," she concluded.

Johansen's daughter, Leah Hennessey, took to Instagram to share the sad news on Monday.

"David is a legend but he's also my very real very sick dad," she wrote alongside a picture of him on her Instagram story. "I have so much to say but I guess I'll be posting about this a lot and I don't have to say it all now. I know how dire so many of our situations are right now, and how much fundraising literally everyone is doing but if you love David or any of the magick (sic) he's brought into the world please just take a minute to read this or share it. Thank you guys as always."

LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS

Leah also included a link to the Sweet Relief Musician Fund. The organization helps raise money for musicians who are struggling with health problems.

His daughter explained on the website that five years ago, Johansen's cancer progressed and he had a brain tumor.

"There have been complications ever since. He’s never made his diagnosis public, as he and my mother Mara are generally very private people, but we feel compelled to share this now, due to the increasingly severe financial burden our family is facing," the website states.

CLICK HERE TO SIGN UP FOR OUR ENTERTAINMENT NEWSLETTER

According to Leah, things took a turn for the worse during Thanksgiving.

"To make matters worse, the day after Thanksgiving, David fell down the stairs and broke his back in two places," she wrote on the website. 

Johansen has since had surgery, but Leah said, "David has been bedridden and incapacitated. Due to the trauma, David’s illness has progressed exponentially and my mother is caring for him around the clock."

Aside from the New York Dolls, Johansen is known for his alter ego, Buster Poindexter. In 1987, his song "Hot Hot Hot" was a Billboard hit. 

Three months after revealing his cancer diagnosis, Dave Coulier is continuing the fight of his life. 

During a recent interview with ABC-WXYZ in Detroit, Coulier's wife, Melissa, said that while the "Full House" alum's battle has gotten "more difficult," they both remain positive and even participate in silly morning rituals that help boost his confidence. 

"He has some really tough days, and as the chemo has been accumulating it gets a little tougher and more difficult," she told the local station on Thursday. 

'FULL HOUSE' STAR DAVE COULIER DIAGNOSED WITH 'VERY AGGRESSIVE' CANCER

"He has such a positive attitude, and you need that in order to really fight it," she continued. "Every morning, if he’s feeling up for it, we try to put on a song and do a little dance party with the dogs, because when you do feel good, you have to celebrate that, too."

"He has had a lot of loss in his life when it comes to having to deal with cancer. He lost his mother, his sister, his niece. His other sister had it," she added. "I think for him, he takes every stride and really pulls strength from seeing the women that were so close in his life to powering through it, and he just wants to honor them."

In November, Coulier, who starred as Joey Gladstone in the beloved TV series "Full House" in the 1980s and 90s, announced that he had been diagnosed with stage 3 non-Hodgkin lymphoma.

‘FULL HOUSE’ STAR DAVE COULIER SAYS SOBRIETY HELPED HIM GRIEVE THE DEATHS OF BOB SAGET, DAD AND BROTHER

The actor and comedian said he was diagnosed in October after experiencing an upper respiratory infection caused by major swelling in his lymph nodes. 

"Three days later, my doctors called me back, and they said, ‘We wish we had better news for you, but you have non-Hodgkin lymphoma, and it's called B cell, and it's very aggressive,'" he told People.

LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS

"I went from, ‘I got a little bit of a head cold’ to ‘I have cancer,’ and it was pretty overwhelming," he added. "This has been a really fast roller-coaster ride of a journey." 

According to the American Cancer Society, B-cell lymphoma is a type of cancer that develops in B-lymphocytes. B-cell lymphomas account for the vast majority of non-Hodgkin lymphomas. Every year, more than 80,000 Americans are diagnosed with non-Hodgkin lymphoma.

"The first thing I said to them was, ‘Wait a minute — cancer?’" Coulier later shared on the "Today" show. "(I was) feeling like I got punched in the stomach, because it never happens to you. You always hear about it happening to someone else."

CLICK HERE TO SIGN UP FOR THE ENTERTAINMENT NEWSLETTER

"My joke is that in four short weeks, I’ve gone from a Virgo to a Cancer," he continued. "I’ve tried to retain a sense of reality but also a sense of humor about it."

"I told Melissa I don’t know why, but I (am) OK with whatever the news (is) going to be, no matter how devastating. . . . I can’t explain where that came from," he added. "I’ve had an incredible life. I’ve had the most amazing people in my life. This has been an extraordinary journey, and I’m OK if this is the end of the journey."

Fox News Digital's Stephanie Giang-Paunon contributed to this post. 

A major annual cancer report has revealed a mix of good news and points of concern.

Cancer diagnoses are expected to exceed two million in 2025, with approximately 618,120 deaths predicted, according to the American Cancer Society’s annual cancer trends report, which was published today in CA: A Cancer Journal for Clinicians.

ACS researchers compiled data from central cancer registries and from the National Center for Health Statistics.

ALCOHOL LINKED TO CANCER RISK IN US SURGEON GENERAL'S NEW ADVISORY

While mortality rates have declined, certain groups are seeing a spike in diagnoses, the report noted.

"Continued reductions in cancer mortality because of drops in smoking, better treatment and earlier detection is certainly great news," said lead author Rebecca Siegel, senior scientific director of surveillance research at the ACS in Georgia, in a press release.

"However, this progress is tempered by rising incidences in young and middle-aged women, who are often the family caregivers, and a shifting cancer burden from men to women, harkening back to the early 1900s, when cancer was more common in women."

Cancer death rates dropped 34% between 1991 and 2022, according to the ACS report.

That equates to approximately 4.5 million deaths avoided due to early detection, reductions in smoking, and improvements in treatment, the report stated.

Several factors likely contributed to this decline, noted John D. Carpten, Ph.D., chief scientific officer at City of Hope, a national cancer research and treatment organization in California.

"I think a big one is smoking cessation and the battle against lung cancer, which has always been the most common form of cancer and is tied to tobacco use," Carpten told Fox News Digital in an on-camera interview.

LIVER CANCER PATIENT GIVEN 6 MONTHS TO LIVE LOSES 76 POUNDS EATING SPECIFIC FOODS

"But without a doubt, I think new and better methods for early detection, and screening for colorectal cancer and other forms of the disease, have also allowed us to see a decrease." 

Lifestyle improvements have also helped to decrease mortality, he said, along with the development of new and better therapies for cancer.

Despite overall declines in mortality, the report revealed that death rates are rising for cancers of the oral cavity, pancreas, uterine corpus and liver (for females).

Some common cancers have also seen an increase in diagnoses, including breast (female), prostate, pancreatic, uterine corpus, melanoma (female), liver (female) and oral cancers associated with the human papillomavirus, the report stated.

Diagnoses for many cancer types are increasing among certain groups.

Cancer rates for women 50 to 64 years of age have surpassed those for men, the report revealed. For women under 50, rates are 82% higher than males in that age group.

As far as what is influencing the "disconcerting trend" in women’s cancers, Carpten said it is likely "highly nuanced" and will require additional research.

"The decrease in fertility and increases in obesity that we’ve seen are risk factors for breast cancer, especially in postmenopausal middle-aged women," he said. 

"But there could be other modifiable risk factors at play, like alcohol and physical activity."

Another trend in the increase in early cancers is occurring in individuals under the age of 50, Carpten noted.

In particular, the report revealed that diagnoses of colorectal cancer in men and women under 65 and cervical cancer in women between 30 and 44 years of age has increased.

The report also discusses inequities in cancer rates among certain ethnic groups, with Native American and Black people experiencing higher diagnoses of some cancer types.

"Progress against cancer continues to be hampered by striking, wide static disparities for many racial and ethnic groups," said senior author Dr. Ahmedin Jemal, senior vice president of surveillance and health equity science at the ACS, in the release.

AI DETECTS OVARIAN CANCER BETTER THAN HUMAN EXPERTS IN NEW STUDY

The report shows mixed trends for children, with diagnoses declining in recent years for patients 14 years of age and younger, but rising for adolescents between 15 and 19.

"Mortality rates have dropped by 70% in children and by 63% in adolescents since 1970, largely because of improved treatment for leukemia," the ACS stated in the release.

The ACS report also warns about "lagging progress" against pancreatic cancer, the third-leading cause of cancer death in the U.S. 

Rates of diagnoses and deaths from the disease type are on the rise.

"Pancreatic is an incredibly deadly form of cancer," Carpten said. 

One of the main issues with pancreatic cancer, he said, is that it sometimes can grow in an individual for up to 10 years before it's detected.

One of the best opportunities for beating pancreatic cancer is early detection, Carpten said. 

"By the time those cancers have advanced, they've spread to the liver or other organs, and they’re almost impossible to cure at that stage," he said.

"If we can identify those cancers when they're at a curable stage, we can improve outcomes."

Making progress in fighting cancer "takes a village," Carpten told Fox News Digital.

"It will require partnerships between the community, the health care system, cancer researchers, government, industry — we all have to work together if we want to continue to see a decrease and an ultimate increase in cures," he said.

Dr. Wayne A. I. Frederick, interim chief executive officer of the American Cancer Society and the American Cancer Society Cancer Action Network (ACS CAN), stated that the report highlights the need to "increase investment in both cancer treatment and care, including equitable screening programs."

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"Screening programs are a critical component of early detection, and expanding access to these services will save countless lives," he said in the release.

For more Health articles, visit www.foxnews.com/health

"We also must address these shifts in cancer incidence, mainly among women. A concerted effort between health care providers, policymakers and communities needs to be prioritized to assess where and why mortality rates are rising."

Fox News Digital reached out to the ACS for further comment.

A Durham, North Carolina, man has turned his life around after receiving grave medical news. 

Derek Barnett, 55, was diagnosed with non-alcoholic fatty liver disease 10 years ago, according to a report from SWNS.

At his heaviest, Barnett weighed 240 pounds and was a size 38.

CAN'T STOP THINKING ABOUT YOUR NEXT MEAL? IT'S CALLED FOOD NOISE, HERE'S WHAT TO DO

Barnett, a construction worker who is currently unemployed due to health issues, brushed off his diagnosis, telling SWNS that he "didn’t think anything of it."

"Everybody’s got a type of thing," he said.

But the man's condition worsened, progressing into cirrhosis and eventually hepatocellular carcinoma, also known as liver cancer.

In January 2024, Barnett was given a letter from his doctor that broke some bad news – he potentially had only six months to live if the cancer continued to grow.

"When they gave me that letter last year, it got real," he reflected.

HAIR GROWTH COULD SLOW DOWN WITH THIS POPULAR DIET PLAN, STUDY REVEALS

"That note said, 'If the cancer gets aggressive, you have six months to live.' I saved it, looked at it every day, and it beat me up."

Barnett’s doctors informed him that the best way to regain his health would be to lose weight – and he knew it was time to get motivated and act.

"I was like, ‘OK, we can do this,’" he told SWNS. "I’m a fruit-aholic. I went on a major fruit diet basically."

Barnett began limiting his diet to "very tiny meals" throughout the day, involving lots of his favorite fruits.

"I can eat a whole watermelon in a day, but I also eat apples, oranges and grapes — whatever’s in season," he said.

‘YO-YO’ WEIGHT LOSS OCCURS BECAUSE OF THIS SURPRISING REASON

"I do protein shakes, too. I’m not a vegetarian, but I don’t eat meat much, because it’s too filling for me."

Barnett recently hit a record-low weight of 164 pounds. He reported that he dropped the pounds by following this diet, and that his "scores are looking fantastic."

"I haven’t weighed this since I was probably 15 years old," he said.

Barnett said he still has work to do in toning his muscles to "catch up to the skin loss," but he continues to push forward.

"My clothes are a little too big and baggy, and it’s hard to afford clothing when you lose weight so quickly, but I feel fantastic," he said.

IS EATING ONCE A DAY A GOOD IDEA? EXPERTS SHARE VARYING OPINIONS ON THE ‘OMAD DIET’

Barnett has also kept the weight off by staying active, despite his physical limitations.

"I have osteoarthritis in my right knee and need a knee replacement," he revealed. "I can’t go jogging or do stairs, but I do what I can."

He reported that his workouts usually involve sitting in chairs and "using little dumbbells."

For more Health articles, visit www.foxnews.com/health

"I’m nonstop, but I do it without hurting myself," he added. "Losing weight is just [about] staying active, finding anything you can possibly do to get off a couch."

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Barnett told SWNS that he will find out the status of his prognosis in February, and that he hopes to inspire others with his successful weight-loss journey.

 "If I can do this, anyone can," he said. "I’ve done everything the doctors told me to do. It’s about eating right, staying active and never giving up."

"I was 55 going on 90," he went on. "Now I’m 55, going back on 20 again."

Barnett hopes to return to work and live a "full, active life," according to SWNS.

"I want to ring that bell next time I see my doctors and tell them I’ve done it," he said. "This is just the beginning."

The U.S. surgeon general has released a new advisory warning of alcohol-related cancer risk.

Dr. Vivek Murthy issued the guidance on Friday following research that has linked alcohol to at least seven types of cancer.

In particular, the advisory notes that alcohol can increase the risk of throat, liver, esophageal, mouth, larynx (voice box), colon and rectal cancers.

DRINKING ALCOHOL IS LINKED TO CANCER, EXPERTS SAY

Alcohol consumption has been named as the "third leading preventable cause of cancer" in the country, the advisory noted, with tobacco and obesity taking the top two spots.

"Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States — greater than the 13,500 alcohol-associated traffic crash fatalities per year in the U.S. — yet the majority of Americans are unaware of this risk," said Murthy in the advisory. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"This Advisory lays out steps we can all take to increase awareness of alcohol’s cancer risk and minimize harm."

The advisory breaks down four different ways in which cancer can increase cancer risk.

In one mechanism, the alcohol breaks down into a chemical called acetaldehyde, which damages DNA and increases cancer risk.

Alcohol also induces "oxidative stress," the advisory warns, which damages protein, DNA and cells, and also causes inflammation.

‘ALCOHOL GENE’ COULD PREDICT HOW COCKTAILS MAY AFFECT YOU — AND THERE’S A TEST FOR IT

In a third mechanism, alcohol changes hormone levels, namely estrogen, which can increase the risk of breast cancer. More than 16% of all breast cancer cases have been linked to alcohol, the advisory states.

Finally, cancer creates conditions in which alcohol is more easily absorbed into the body.

Individual risk for alcohol-related cancers will also depend on "a complex interaction of biological, environmental, social and economic factors," the same source stated.

In the new advisory, Murthy calls for a warning label to be placed on alcoholic beverages stating that they may increase cancer risk.

The advisory also calls for a "reassessment of the guideline limits" for alcohol consumption and encourages people to be cognizant of the risk when deciding how much to consume.

The surgeon general also calls for doctors, health professionals and community groups to emphasize the link between alcohol and cancer to help raise awareness of the risk.

Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, applauded Murthy's advisory.

"Too many Americans are living with an outdated assumption that some amount of alcohol is not only harmless, but also good for you," he told Fox News Digital. "Increasing evidence shows that isn't true."

Though wine and other alcoholic beverages may relieve stress and dilate arteries in the short term, the doctor warned that alcohol is a "proven toxin" with direct links to liver, heart and brain disease. 

"Even though traditional advice has been up to one drink a day for women and two drinks per day for men, in fact, no amount of alcohol is healthy," Siegel said.

Multiple studies have shown that 25% of people increased their alcohol use during the pandemic, according to Siegel.

For more Health articles, visit foxnews.com/health

"This was in part because of stress and also because of social isolation — and the numbers have persisted since the pandemic ended," he said.

"The timing of this advisory is right on the mark."

2024 was packed with health care innovations, from a new blood test detecting Alzheimer’s disease to deep brain stimulation reversing paralysis.

Heading into the New Year, medical experts are predicting even more medical advances for 2025.

Researchers from Mass General Brigham, a health care system in Boston, Massachusetts, shared with Fox News Digital some of the scientific developments and breakthroughs they expect to see, which are also published on the hospital’s website.

7 OF GOOGLE’S MOST-SEARCHED HEALTH QUESTIONS IN 2024, WITH EXPERT RESPONSES

1. "I anticipate we are going to see continued breakthroughs and growth in immunotherapy for cancer, particularly with FDA approvals and commercialization of cell therapies for solid tumors. The field is also poised to make great strides in using these technologies for other conditions, like autoimmune diseases."

Bryan Choi, MD, PhD
Investigator, Department of Neurosurgery
Massachusetts General Hospital

2. "I predict novel discoveries and innovative strategies for early cancer detection and prevention will dramatically impact patient care in the coming year. With the proven success of immunotherapy for cancer treatment, there is an emerging interest in utilizing the patient’s own immune system for cancer prevention, especially in high-risk populations. This area of research is expanding rapidly and will likely generate actionable targets for investigations in patients."

Shawn Demehri, MD, PhD
Investigator, Mass General Cancer Center
Massachusetts General Hospital

3. "The current standard for treating patients with clinical stage 2 or 3 triple-negative breast cancer is to administer chemotherapy in addition to immunotherapy prior to surgery. This combination therapy leads to a better response than chemotherapy alone. However, immunotherapy comes with added toxicities that can lead to lifelong complications."

"In 2025, I anticipate significant progress will be made in identifying biomarkers in a patient’s peripheral immune system that will help determine which patients require the addition of immunotherapy and those who will do well with chemotherapy alone. This would be an important step in further personalizing breast cancer care and reducing long-term side effects."

Elizabeth Mittendorf, MD, PhD, MHCM
Investigator, Department of Surgery
Brigham and Women’s Hospital

4. "In basic research, single-cell technologies have been advancing at an accelerated pace. In 2025, I believe we will likely see major breakthroughs in spatial transcriptomics and sub-cellular high-resolution imaging, particularly in the context of embryo development and understanding of cancer progression and resistance."

Raul Mostoslavsky, PhD
Investigator, Krantz Family Center for Cancer Research
Massachusetts General Hospital

5. "I believe we will see a greater focus on the long-term impact of multiple environmental factors on disease states, such as cancer development processes. There is a misconception that many non-hereditary diseases, such as non-hereditary cancer, are the result of short-term risk factor exposure. I think that research in the coming year will shift focus on the long-term impacts of multiple disease-causing factors."

Shuji Ogino, MD, PhD, MS
Chief of Molecular Pathological Epidemiology Program, Department of Pathology
Brigham and Women’s Hospital

1. "I anticipate we’ll see an uptick in usage of artificial intelligence (AI) to support physicians while they care for patients, streamline workflows, and improve diagnostics and treatments in 2025. We’re also likely to see expanded use of robotics and AI in complex surgeries, particularly for brain and spine procedures."

E. Antonio Chiocca, MD, PhD, FAANS
Executive Director, Center for Tumors of the Nervous System
Mass General Brigham

2. "I predict that advances in non-invasive brain stimulation will change how we care for patients with brain disease, including accelerated protocols that improve symptoms in days rather than weeks, personalized protocols that target the most bothersome symptom in each patient, and at-home devices that make brain stimulation accessible to more patients."

Michael Fox, MD, PhD
Director, Center for Brain Circuit Therapeutics
Brigham and Women’s Hospital

THE YEAR IN CANCER: ADVANCES MADE IN 2024, PREDICTIONS FOR 2025

3. "Advances in focused ultrasound technology offer the potential for non-invasive, targeted, and temporary opening of the blood-brain barrier. This could allow therapies that were previously ineffective — due to their inability to cross the blood-brain barrier to reach their target in the central nervous system — to directly target tissues. I think we will see a breakthrough in this area of research in the next year, enabling treatments for a wide range of brain disorders, including neurological, psychiatric and neurosurgical conditions."

Alexandra Golby, MD
Investigator, Neurosciences Center
Brigham and Women’s Hospital  

4. "Starting in 2025, it will become possible to administer transcranial magnetic stimulation to treat depression over the course of just days instead of weeks, which, aided by pharmacological co-agents, will still lead to a very high remission rate in treatment-resistant patients."

Andreas Horn, MD, PhD
Director, Center for Brain Circuit Therapeutics
Brigham and Women’s Hospital

5. "I predict that the prevention of dementia, stroke and depression will become a cornerstone of patient-directed primary care. In 2024, we saw the publication of several high-impact validation studies of the Brain Care Score (BCS), a tool designed to help people everywhere use the most robust science to guide their daily lifestyle choices and reduce their risk of dementia, stroke and depression by up to 50%. In parallel, we have laid the groundwork to empower people everywhere to use the BCS routinely, and to bring it with them to their next primary care visit with a health care provider."

Jonathan Rosand, MD, MSc
JP Kistler Endowed Chair in Neurology
Co-Founder, McCance Center for Brain Health
Massachusetts General Hospital

6. "I foresee advances on several fronts of dementia care as a major theme for health care in 2025. This includes AI-assisted approaches to improve early diagnosis, novel ways of delivering personalized treatments, and advances in care delivery as the Centers for Medicare & Medicaid Services-developed GUIDE (Guiding an Improved Dementia Experience) Model of Care is implemented nationwide. I also predict that caregiving for persons with dementia will gain further recognition as a major element of health care, requiring more resources and attention."

Ipsit V. Vahia, MD
Investigator, Division of Geriatric Psychiatry
McLean Hospital 

1. "I believe in 2025 we can expect to see the completion of the first large outcomes-focused clinical trial from a group of new medications that target lipoprotein(a), a unique type of 'bad cholesterol' that increases a patient’s risk for cardiovascular disease. Up to this point, the treatment paradigm for patients with elevated lipoprotein(a) has been to aggressively modify other risk factors, but we may soon have more targeted treatment options."

Michael Honigberg, MD, MPP
Investigator, Cardiology Division
Massachusetts General Hospital

STEM CELL THERAPY TO CORRECT HEART FAILURE IN CHILDREN COULD 'TRANSFORM LIVES'

2. "Cardiac critical care has transformed into its own discipline, but remains largely reactive to treating patients as they become sicker. I envision that in 2025, the discovery of molecular biomarkers will shift the care paradigm to a more proactive approach. Molecular biomarkers may help us identify patients most at risk of disease and start interventions earlier, maybe even preventively."

Edy Kim, MD, PhD
Investigator, Pulmonary Division
Brigham and Women’s Hospital

3. "I predict that in 2025, we will see significant advancements in women's health research. In particular, I hope to see major breakthroughs that improve quality of life and cardiovascular health in mid-life/menopausal women, a group that has been historically underappreciated."

Emily S. Lau, MD, MPH
Investigator, Cardiometabolic Health and Hormones Clinic
Massachusetts General Hospital

4. "In 2025, I anticipate we will see the introduction of two intertwined advances. First, the integration of artificial intelligence-facilitated algorithms for the early detection of cardiovascular illness, which will move us closer toward early prevention. We also envision a focus on using genetically informed treatments to reduce the risk of atherosclerotic heart disease, valvular heart disease and heart failure. Together, these important advances will usher in an era of personalized health care in cardiovascular disease."

Mandeep R. Mehra, MBBS, MSc
Executive Director, Center for Advanced Heart Disease
Brigham and Women’s Hospital

5. "In the coming year, I anticipate a marked increase in focus on cardio-kidney-metabolic health, necessitating new patient-centered models of interdisciplinary care."

Pradeep Natarajan, MD, MMSc
Director, Preventive Cardiology
Massachusetts General Hospital

1. "In 2025, I believe we will uncover the answers to remaining questions about nutrient metabolism and why a calorie is not a calorie, thereby improving our understanding of why some people gain weight."

Caroline Apovian, MD
Co-Director, Center for Weight Management and Wellness
Brigham and Women’s Hospital

2. "In the coming year, I see artificial intelligence being integrated more into health care as a supplement to physician knowledge and intuition. With the amount of biomedical data we are generating, I predict AI tools will improve our ability to interpret and apply the most salient information to individual patients, resulting in a personalized approach to patient care. I also predict that AI will continue to greatly reduce the administrative burden on providers and enable them to spend more time with their patients."

William Hwang, MD, PhD
Investigator, Center for Systems Biology, Krantz Family Center for Cancer Research, Department of Radiation Oncology
Massachusetts General Hospital

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

3. "I think in 2025, we will see the implementation of generative artificial intelligence language models (i.e., chatbots) for some aspects of routine clinical care, such as the preparation of patient communications, generation of preliminary diagnostic test reports, or summarization of patient medical records."

Shaan Khurshid, MD, MPH
Investigator, Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias
Massachusetts General Hospital

4. "In 2025, I think we will recognize the power of drones and begin to use them to transform the way we deliver health care by making the home the center of care. Drone-facilitated care will impact primary care, urgent and emergency care, and even enable public health leaps by bringing care directly to patients in ways we never thought possible (or maybe thought were possible only for the Jetsons)."

David Levine, MD, MPH, MA
Clinical Director of Research and Development
Mass General Brigham

5. "Increased access to emerging technologies and personalized data, combined with information specifically tailored for the individual, will drive self-care in health and wellness in more patients, initially in preventative medicine, in the next year. This phenomenon will begin to impact chronic disease management and progressively more complex conditions and will accelerate devolution of care and responsibility for many conditions to the patient — who is often best placed to understand their own health."

Calum A. MacRae, MD, PhD
Vice Chair for Scientific Innovation
Brigham and Women’s Hospital

For more Health articles, visit www.foxnews.com/health

6. "Treatments for rare genetic diseases are rapidly being translated to clinics. With close to 40 gene and cell therapies approved and hundreds expected to come down the pipeline, I believe that in 2025, we will see many more patients benefiting from genetic therapies."

Susan A. Slaugenhaupt, PhD
Scientific Director, Mass General Research Institute
Massachusetts General Hospital

Kate Middleton remarked this week about how relatable going through cancer is for so many people while making a rare comment about her battle with the disease over the last year. 

"The amount of people who have written this year is extraordinary and I think cancer just really does resonate with so many families," the Princess of Wales told a health care worker. She was speaking to the public in Sandringham after the royal family left their Christmas Day church service. 

The royals always spend Christmas at their Sandringham estate in Norfolk, England. 

PRINCE HARRY, MEGHAN MARKLE'S ‘IMPORTANT’ REASON FOR SPENDING CHRISTMAS AT HOME IN CALIFORNIA REVEALED

The health care worker who spoke to the princess, who was identified as Rachel Anvil of Cambridge’s Royal Papworth Hospital, according to the New York Post, called Kate an "inspiration" to cancer patients for the way she handled her own cancer battle. 

Anvil noted that she had started her career in a cancer unit, and added that having someone "so influential" be open about her own struggle was helpful to others dealing with the disease. 

"People like you are doing all the hard work out there," Kate demurred in a video posted to Instagram of the exchange by Anvil’s mother, according to the Post. 

The princess added that she was "hugely grateful" for the work people like Anvil do for patients. 

"We’re all behind you, never forget that," another person, identified by the Post as Anvil’s mother, told the princess — who thanked her. 

LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS

The 42-year-old royal announced she had been diagnosed with cancer in March, two months after she underwent planned abdominal surgery in January. 

She returned for her first public engagement since Christmas Day 2023 in June for the Trooping the Colour parade. 

CLICK HERE TO GET THE FOX NEWS APP

In September, Kate announced she had finished her round of preventative chemotherapy, although she said her path to full recovery would be long, and that she would take it day by day. 

CLICK HERE TO SIGN UP FOR THE ENTERTAINMENT NEWSLETTER

She added that she would undertake some limited engagements through the end of the year, which included her second annual "Together at Christmas" concert at Westminster Abbey earlier this month. 

The princess was accompanied on Christmas Day by her husband Prince William, their three children, Prince George, 11, Princess Charlotte, 9, and Prince Louis, 6, and her in-laws King Charles III and Queen Camilla. 

Charles announced earlier this year that he was also diagnosed with cancer and has been undergoing treatments. 

Fox News Digital's Stephanie Nolasco contributed to this report. 

At the beginning of 2024, the American Cancer Society predicted that 2,001,140 new cancer cases and 611,720 cancer deaths would occur in the United States.

Now, as the year draws to a close, experts are looking back and reflecting on the discoveries and advances that have been made in the field of cancer treatment and prevention.

Fox News Digital spoke with four oncologists from the Sarah Cannon Research Institute in Nashville, Tennessee, about the most notable accomplishments of 2024 and what they see on the horizon for 2025. 

5 CANCER TYPES WHERE SCREENINGS SAVE THE MOST LIVES

See the answers and questions below. 

A: In the field of lymphomas, we see growing momentum for therapies that use the patient's own immune system to fight their cancer, such as CAR T-cell therapy and bispecific antibodies. 

These are treatments that are now being studied and are making an impact earlier in the disease course, including one now being studied as the very first treatment a patient might receive for their lymphoma. 

PANCREATIC CANCER PATIENT SURVIVAL DOUBLED WITH HIGH DOSE OF COMMON VITAMIN, STUDY FINDS

These treatments are helping us to be less dependent on chemotherapies (which may be effective but have broad side effects) for the treatment of lymphomas.  

A: Every year we are improving the curative treatment options we have for specific types of lymphomas, such as diffuse large B-cell lymphoma (DLBCL), which is the most common lymphoma we see. 

We are also gradually becoming better able to offer these treatments closer to – or in – patients’ homes and communities, so they can receive the best care as close to home as possible. 

I believe that in 2025, we will continue to see more advancement in immunotherapies, development of more targeted therapies (including oral medicines), and hopefully soon the approval of next generations of immunotherapies that may work for patients who have already received today's immunotherapies but need more treatment options.

A: It has changed and evolved dramatically. A decade ago, care for lymphomas was primarily chemotherapy-based. Now, we are shifting rapidly away from chemotherapies in some types of lymphomas in favor of immunotherapies and targeted oral therapies that lead to excellent long-term outcomes for patients, with fewer side effects than historical treatments.

A: We think of lymphomas as diseases of aging for most patients. Some patients may have select risk factors, such as being on specific immunosuppressants or having exposure to very specific industrial chemicals. 

Those risks may or may not be so modifiable for patients, and they represent the minority of patients who develop lymphoma. 

AI DETECTS WOMAN’S BREAST CANCER AFTER ROUTINE SCREENING MISSED IT: 'DEEPLY GRATEFUL'

While it is not entirely clear what modifiable risks patients may have, there is ongoing work to help better answer that question. However, we know that the better general health someone is in, the more likely they are to have any and all treatment options available to them. 

I would say that for most people, exercising regularly, eating well and sleeping regularly are important.

A: There is great hope and a lot of exciting science happening to help us drive toward more cures, more effective treatments and less toxic treatments for lymphomas. 

We have already made major strides in the last decade, and we continue to build on that momentum through clinical trials that provide early access to cutting-edge therapies. 

For patients, participating in clinical trials may help to close that time gap between the treatments that are broadly available today and the treatments we expect to be available years from now. 

They also provide a way for patients to contribute positively to the care patients in future generations may receive, which I have been told by many of my patients is something they really want to do and something that is important to them.

A: The two most exciting focuses of 2024 were 1) expansion of targeted therapies in the curative setting for hormonally driven breast cancer and 2) antibody drug conjugates. 

First, three different CDK4/6 inhibitors have been approved in the metastatic setting, and they improve survival and outcomes. 

In 2024, we saw the approval of a second one in the curative setting, enabling us to identify the highest-risk patients and offer them something additional to endocrine therapy to improve cure rates.

Second, we now have multiple antibody drug conjugates approved across all types of breast cancer. These therapies target a chemotherapy drug directly to the tumor via an antibody-honing mechanism and largely spare normal body cells.

A: I anticipate seeing more targeted agents in 2025 and the approval of antibody drug conjugates in curative early breast cancer — currently, most are only approved in metastatic cancer.

[I also anticipate] drugs that are better tolerated with decreased side effects for patients, and a continued emphasis on personalized medicine. 

A: In 2024, truly personalized medicine is possible, from mutation testing to direct targeted therapy to what a cancer needs to grow — as well as being able to provide many HR+ breast cancer patients with curative chemotherapy through personalized risk stratification assays.

A: Continued breast screening with mammograms yearly is really important to find cancers earlier when a cure is more likely.  

People can also reduce their risk through avoiding alcohol and cigarettes and making sure they get regular exercise and maintain a normal body weight.

A: In 2024, precision cancer treatment made big strides with many new drug approvals by the FDA, specifically for treatments guided by specific biomarkers, which means treatments can be more precisely tailored to the genetic makeup of a person's cancer. 

BREAST CANCER VACCINE UPDATE FROM CLEVELAND CLINIC: ‘A NEW ERA’

A key change was moving some therapies from faster, temporary approval processes to full approval, showing strong evidence that these targeted therapy drugs, such as tepotinib and amivantamab for certain types of lung cancer, are effective and safe. 

There were also new drug approvals for rare cancers, including tovorafenib, a BRAF precision medicine for a rare type of brain tumor in children, and afamitresgene autoleucel, a type of immunotherapy for a rare cancer called synovial sarcoma. This highlights important progress in treating these challenging conditions.

We have also seen the approval of precision therapies that work on different types of cancer — not just one specific cancer. This is what we call "tissue-agnostic therapies." 

One such drug is an antibody drug conjugate called trastuzumab deruxtecan, which acts like a smart missile targeting HER2-positive cancers. Another is repotrectinib, which works on any cancer that has the NTRK biomarker, regardless of where it is in the body.

A: By 2025, cancer research is likely to see advancements in precision oncology and the use of artificial intelligence. 

In precision oncology, we can expect more personalized treatment plans based on an individual's genetic makeup, leading to more effective and targeted therapies with fewer side effects. 

Additionally, AI will likely play a larger role in analyzing vast amounts of data to identify new drug targets, predict patient responses to treatments and enhance early detection methods. 

These advancements have the potential to improve cancer diagnosis, treatment and overall patient outcomes.

A: In the last 10 years, cancer treatment has changed dramatically. By using genetic information to create personalized treatments that match the specific details of each person's cancer, therapies are more effective and less harmful. 

New technologies such as analyzing cancer's genetic profile, blood tests that detect cancer, and treatments that boost the immune system have greatly improved how we diagnose, track and treat cancer, leading to better results for patients.

A: To lower the risk of cancer, people can avoid smoking, eat a healthy diet, exercise regularly, limit alcohol, protect their skin from the sun and maintain a healthy weight.

A: Get vaccines for viruses like HPV and hepatitis B, as they can lead to some cancers. Also, go for regular health checks to catch any signs of cancer early. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

We are in a unique time when treatments can be tailored specifically to each person, and many of these are available through clinical trials. If you or a loved one is diagnosed with cancer, ask your doctor if there are any clinical trials that might be a good fit.

A: The first cellular therapy, Lifileucel, was approved in melanoma after decades of research in academia and industry. 

This is a significant step forward for both patients with melanoma, but also the field of oncology at large.

A: As we look to bring effective therapies from the metastatic setting into early stages of disease, we are anxiously awaiting updates in the next 18 to 24 months for a number of ongoing trials for combination therapy for patients with high-risk stage 2 or 3 melanoma.

A: Outcomes for melanoma have significantly changed over the past 10 years. 

For more Health articles, visit www.foxnews.com/health

The five-year survival for patients with a diagnosis of stage 4 melanoma was less than 5% before 2010, and now clinical trials have shown that more than 50% of patients are still alive 10 years after being treated with FDA-approved immune checkpoint inhibitors.

A: Lifelong sun protective measures, such as wearing sunscreen, avoiding direct UV exposure during peak hours of 10 a.m. to 2 p.m., and avoiding tanning beds continue to be important starting at an early age.

Conservatives and allies of President-elect Trump are dismantling a narrative put forth by Democratic lawmakers such as Sen. Elizabeth Warren that Republicans blocked funding for childhood cancer research in the spending bill, pointing to a stand-alone bill that had languished in the Democratic-controlled Senate for months. 

Congress passed a pared-down spending bill early Saturday morning as the government careened toward a prolonged shutdown. The bill’s passage followed tech billionaire Elon Musk and other Trump allies slamming a more than 1,500-page piece of legislation earlier last week as "outrageous" and "​​full of excessive spending, special interest giveaways and pork barrel politics," demanding lawmakers return to the negotiation table. 

The Senate advanced a third version of a short-term funding bill on Saturday morning, following negotiations that whittled down the legislation to not include measures such as providing lawmakers a pay raise. 

As negotiations were hashed out, Warren and other Democrats attempted to slam Republicans for allegedly blocking funding for childhood cancer research in the bill. 

TRUMP SET TO DELIVER FIRST RALLY-STYLED SPEECH SINCE DECISIVE ELECTION WIN: 'BIGGEST CONSERVATIVE MOVEMENT'

"We actually are now getting our first taste – this is it live and in living color – about what it means to have this DOGE," Warren said on CNN as the government prepared to shut down on Friday evening. 

LAWMAKERS REACT TO STOPGAP FUNDING AND AVERTING GOVERNMENT SHUTDOWN

DOGE, the Department of Government Efficiency, is an upcoming presidential advisory committee that will be led by Musk and Vivek Ramaswamy to cut excessive government spending and slash the size of the government under Trump’s second administration. 

"Right out here, and what that's going to mean. And that's where Elon Musk's fingerprints are all over this. Because, for example, what this bill says is all, let's get rid of funding for research on pediatric cancer. Let's get rid of funding for research on early detection of cervical cancer and breast cancer. Let's get rid of funding for research on children with Down Syndrome and on sickle cell anemia. Let's get rid of those things so that we could make way for tax cuts for billionaires, that is Elon Musk's notion of efficiency," she continued. 

PRESIDENT BIDEN SIGNS STOPGAP FUNDING BILL INTO LAW, NARROWLY AVERTING SHUTDOWN

While the Democratic Party’s war room published a press release declaring: "Trump and his MAGA minions in Congress have decided to threaten a government shutdown for his political gain – and now they’ve stooped as low as cutting child cancer research."

"​​Lyin’ Liz Warren aka Pocahontas," Musk shot back in response to Warren’s comments, referring to Trump’s common taunt against Warren. 

Other conservatives and Trump allies slammed the narrative that the GOP blocked funding for childhood cancer research, pointing to a stand-alone bill that passed in the Republican-led House in March, and had for months languished in the Democratic-led Senate. 

WHITE HOUSE PRESSED ON BIDEN REFUSING TO SPEAK PUBLICLY AHEAD OF SHUTDOWN

"Elizabeth Warren repeats the lie that @elonmusk and Republicans blocked funding for child cancer research. A stand alone bill for child cancer research funding passed the Republican controlled House in March and got held up in the Democrat controlled Senate," popular conservative X account Libs of TikTok posted in response to Warren’s CNN interview. 

"Democrats blocked funding for child cancer research."

The House passed a stand-alone bill on March 5, at a vote of 384-4, that allocated millions of dollars per year for pediatric research through 2028. The bill was delivered to the Senate on March 6, but Senate Majority Leader Chuck Schumer, D-N.Y., had not taken action on the legislation, sparking condemnation from conservatives months later that Democrats used the research funding as a "bargaining chip." 

TRUMP-BACKED SPENDING BILL GOES DOWN IN FLAMES AS SHUTDOWN LOOMS

"Democrats are using children with cancer as political shields in the shutdown game to blame Republicans after using them as political shields to help defend all the slop Democrats wanted included in the bill. If this funding is so important, it can be passed on its own as a stand-alone bill. You know, like how the government is supposed to work, instead of cramming hundreds of useless proposals into the same bill as pediatric cancer research funding in a 1,500-page mess that no one actually reads so that you can attack anyone who doesn’t support the useless stuff by claiming they hate children with cancer," an op-ed published in the Washington Examiner outlined. 

A review of the legislation shows that on Friday​​ evening, the Senate passed the legislation by a voice vote, following condemnation targeting the GOP for allegedly blocking funding for the research.

The legislation extends $12.6 million a year in cancer research funding through 2031. 

Fox News Digital reached out to Warren’s office for additional comment Sunday morning, but did not immediately receive a reply.